Pediatrix Medical Group (NYSE:MD) Upgraded at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a research note issued to investors on Wednesday.

MD has been the subject of a number of other research reports. Jefferies Financial Group increased their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Truist Financial raised their price target on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. UBS Group lifted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Mizuho increased their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Stock Performance

MD opened at $14.15 on Wednesday. The business has a 50 day moving average price of $12.53 and a two-hundred day moving average price of $9.84. Pediatrix Medical Group has a 1-year low of $6.62 and a 1-year high of $16.41. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -4.62, a price-to-earnings-growth ratio of 2.18 and a beta of 1.55. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.29 EPS. Research analysts predict that Pediatrix Medical Group will post 1.25 EPS for the current fiscal year.

Insider Activity

In other news, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 18.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James D. Swift sold 11,100 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares in the company, valued at $1,834,310.79. This represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,808 shares of company stock valued at $751,277. 2.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its stake in Pediatrix Medical Group by 79.2% in the first quarter. BNP Paribas Financial Markets now owns 41,728 shares of the company’s stock valued at $419,000 after buying an additional 18,438 shares in the last quarter. Illinois Municipal Retirement Fund lifted its position in Pediatrix Medical Group by 8.8% in the 1st quarter. Illinois Municipal Retirement Fund now owns 49,526 shares of the company’s stock valued at $497,000 after acquiring an additional 4,013 shares in the last quarter. ProShare Advisors LLC lifted its position in Pediatrix Medical Group by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock valued at $170,000 after acquiring an additional 1,167 shares in the last quarter. Vanguard Group Inc. boosted its stake in Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after purchasing an additional 164,333 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Pediatrix Medical Group by 4.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 87,369 shares of the company’s stock worth $877,000 after purchasing an additional 3,669 shares in the last quarter. 97.71% of the stock is currently owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.